
Telix Pharmaceuticals (NASDAQ:TLX) updated on Tuesday its commercial and operational performance for the third quarter of fiscal 2025.
Telix reported third-quarter revenue of $206 million, up 53% year over year and 1% sequentially. PSMA imaging revenue increased 17% to $155 million, and RLS third-party revenue reached $47 million.